Adoptive Immunotherapy

Protocol Shows Strong Anti-Viral and Anti-Tumor Effect in Patients

Published in Cancer Weekly, June 10th, 1996

Long-term immunity against Epstein-Barr virus (EBV) lymphoproliferative disease is possible in immunocompromised patients with adoptive immunotherapy.

Infusion of donor leukocytes has been shown to have a graft-vs-leukemia (GVL) effect after bone marrow transplantation. It has also been shown to be an effective treatment for EBV-associated posttransplant lymphoproliferative disease. It has been assumed that the beneficial effects of these donor grafts are mediated by tumor- or virus-specific cytotoxic T lymphocytes (CTLs) that are contained within the bulk T-cell population.

In spite of the ability of these unmanipulated lymphocytes to mediated...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (1996-06-10)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry